We are live on ! Find out more
RXRX icon

Recursion Pharmaceuticals
RXRX

75 hedge funds and large institutions have $1.71B invested in Recursion Pharmaceuticals in 2021 Q2 according to their latest regulatory filings, with 75 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

27.91% more ownership

Funds ownership: 0% → 27.91% (+28%)

Holders
75
Holders Change
+75
Holders Change %
–
% of All Funds
1.31%
Holding in Top 10
6
Holding in Top 10 Change
+6
Holding in Top 10 Change %
% of All Funds
0.1%
New
75
Increased
–
Reduced
–
Closed
–
Calls
$705K
Puts
–
Net Calls
+$705K
Net Calls Change
+$705K

Top Buyers

1
Baillie Gifford & Co
Baillie Gifford & Co
United Kingdom
+$548M
2
LCM
Laurion Capital Management
New York
+$114M
3
Vanguard Group
Vanguard Group
Pennsylvania
+$79.4M
4
AIM
ARK Investment Management
Florida
+$70.4M
5
Fidelity Investments
Fidelity Investments
Massachusetts
+$65.5M

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
ZP
51
Zimmer Partners
New York
$365K +$296K +10,000 New
MIM
52
MetLife Investment Management
New Jersey
$318K +$258K +8,708 New
VOYA Investment Management
53
VOYA Investment Management
Georgia
$298K +$242K +8,171 New
Bank of America
54
Bank of America
North Carolina
$288K +$233K +7,877 New
FIA
55
Foundations Investment Advisors
Arizona
$282K +$208K +7,020 New
Simplex Trading
56
Simplex Trading
Illinois
$257K +$209K +7,066 New
MLICM
57
Metropolitan Life Insurance Company (MetLife)
New York
$243K +$197K +6,667 New
Victory Capital Management
58
Victory Capital Management
Texas
$242K +$196K +6,620 New
Invesco
59
Invesco
Georgia
$205K +$166K +5,612 New
ProShare Advisors
60
ProShare Advisors
Maryland
$200K +$162K +5,482 New
SO
61
STRS Ohio
Ohio
$178K +$145K +4,900 New
TRCT
62
Tower Research Capital (TRC)
New York
$91K +$74.3K +2,512 New
Legal & General Group
63
Legal & General Group
United Kingdom
$75K +$60.7K +2,051 New
Osaic Holdings
64
Osaic Holdings
Arizona
$69K +$55.9K +1,890 New
AIP
65
Ameritas Investment Partners
Nebraska
$60K +$49K +1,657 New
Royal Bank of Canada
66
Royal Bank of Canada
Ontario, Canada
$53K +$42.8K +1,445 New
PCM
67
Pinz Capital Management
New York
$45K +$36.7K +1,240 New
Morgan Stanley
68
Morgan Stanley
New York
$41K +$33.6K +1,136 New
Citigroup
69
Citigroup
New York
$37K +$29.8K +1,006 New
Rockefeller Capital Management
70
Rockefeller Capital Management
New York
$36K +$29.6K +1,000 New
RE
71
RBC Europe
United Kingdom
$30.7K +$24.9K +840 New
UBS Group
72
UBS Group
Switzerland
$26K +$20.7K +700 New
EVM
73
Eaton Vance Management
Massachusetts
$7K +$5.92K +200 New
Carson Wealth (CWM LLC)
74
Carson Wealth (CWM LLC)
Nebraska
$1K +$888 +30 New
AIG
75
American International Group
New York
$432 +$350K +11,839 New
1 2
3

RXRX Hedge Fund Activity: Q2 2021 in Review

75 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Recursion Pharmaceuticals (RXRX) for Q2 2021, worth a combined $1.71B.

Buyers outnumbered sellers: 75 funds opened new RXRX positions and 0 closed out — a net gain of 75 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was Baillie Gifford & Co, opening a new position worth an estimated $548M.

  • 75 institutional investors held Recursion Pharmaceuticals (RXRX) as of Q2 2021, up from 0 in Q1 2021.
  • Funds reported $1.71B of Recursion Pharmaceuticals stock for Q2 2021.
  • 75 funds opened new Recursion Pharmaceuticals positions in Q2 2021 and 0 closed out, a net change of +75 holders.
  • The largest Recursion Pharmaceuticals buyer in Q2 2021 was Baillie Gifford & Co, an estimated $548M added.

Based on aggregated 13F filings for Q2 2021.